Firstly, oral lipid-lowering agents treatment in patients with diabetes and dyslipidemia is effective for HEs reduction and subfoveal lipid migration in CME [31]; however, we did not take into account oral administration of lipid-lowering agents when assessing the effect of anti-VEGF agents on HEs development. This evidence concerns the gene VEGFA and hypereosinophilic syndrome.